Recombinant Mouse E3 ubiquitin-protein ligase RNF19B (Rnf19b)

What is RNF19B and what is its primary function?

RNF19B is a member of a small family of E3 ubiquitin ligases with a characteristic cysteine-rich RING-IBR-RING (RBR) domain that mediates the ubiquitination of multiple substrates . It was initially discovered in 1999 and has since been recognized for its integral function in innate immune responses, particularly in natural killer (NK) cells and macrophages. RNF19B catalyzes the transfer of ubiquitin to target proteins, which can lead to proteasome-mediated degradation or altered protein localization and function . One of its key functions is mediating K48-linked polyubiquitination of target proteins such as RAC1, leading to their degradation via the ubiquitin-proteasome pathway .

What is the structural composition of RNF19B?

RNF19B contains several functional domains essential for its activity:

• A characteristic RBR (RING1-IBR-RING2) core domain containing a catalytic cysteine (C316 in human RNF19B)

• At least two transmembrane domains

• An N-terminal extension

• A C-terminal regulatory domain

The RBR core and at least one of the transmembrane domains are essential for its ubiquitin ligase activity . Unlike conventional RING E3 ligases, RBR E3 ligases like RNF19B require transfer of ubiquitin from the E2 ligase to a catalytic cysteine in their RING2 domain prior to transfer to a substrate .

How is RNF19B expression regulated in cells?

RNF19B expression is tightly regulated and can be induced by various stimuli:

Under baseline conditions, both NK cells and macrophages express minimal amounts of RNF19B, but its expression is rapidly upregulated following stimulation . The RNF19B promoter contains binding sites for multiple transcription factors including IRF-1, IRF-2, and NFκB proteins p50 and p65/RelA, suggesting complex transcriptional regulation .

Which cell types express RNF19B?

RNF19B is expressed by various cell types, predominantly in the immune system:

• Natural killer (NK) cells

• CD8+ cytotoxic T cells

• Bone marrow-derived macrophages (BMDM)

• Peripheral blood monocytes

• Splenic and peritoneal macrophages

• Limited expression in non-immune cells:

  • Testicular cells (associated with ppp1cc)

  • Mouse tracheal epithelial cells (when treated with IFNγ)

What are the known substrates of RNF19B and their biological significance?

RNF19B has several identified substrates, with RAC1 being particularly well-characterized:

RAC1 is a key substrate of RNF19B. The enzyme catalyzes K48-linked polyubiquitination of RAC1, leading to its proteasomal degradation . This is particularly significant as RAC1 is best known for its role in regulating cytoskeletal dynamics and cell migration. By downregulating RAC1, RNF19B can inhibit cancer cell migration and potentially metastasis. In non-small-cell lung cancer (NSCLC), the DIRAS3-RNF19B-RAC1 axis is associated with malignant progression, with DIRAS3 promoting the binding of RAC1 to RNF19B and enhancing RAC1 degradation .

How does RNF19B contribute to immune function?

RNF19B (NKLAM) plays critical roles in multiple immune cell types:

• In NK cells:

  • Required for maximal cytotoxic activity

  • Localizes to lytic granule membranes

  • Contributes to cytokine production

• In macrophages:

  • Enhances phagocytic killing capacity

  • Mediates cytokine production following pathogen stimulation

These functions position RNF19B as an important modulator of both innate immune surveillance and response to pathogens . The interferon-inducible nature of RNF19B suggests it participates in amplifying immune responses during infection or inflammation.

What is the evidence linking RNF19B to cancer progression?

RNF19B expression is significantly altered in several cancer types:

• In NSCLC, RNF19B protein levels are lower compared to normal tissues

• RNF19B has been identified as a novel biomarker affecting prognosis in neuroblastoma patients

• The DIRAS3-RNF19B-RAC1 axis is associated with NSCLC malignant progression

Chi-squared tests performed on tissue microarrays containing 186 normal and NSCLC patient samples demonstrated an inverse correlation between DIRAS3 and RAC1 levels, with RNF19B acting as an intermediary in this pathway . Patients with high DIRAS3 and RNF19B levels often displayed low RAC1 expression and vice versa. This pattern suggests that reduced RNF19B expression in cancer may contribute to increased RAC1 levels, promoting cell migration and potentially metastasis.

How does the RNF19B mechanistic pathway differ from other E3 ubiquitin ligases?

RNF19B belongs to the RBR family of E3 ubiquitin ligases, which operate through a unique hybrid mechanism:

• Unlike conventional RING E3 ligases that directly transfer ubiquitin from E2 to substrate

• RBR ligases like RNF19B first accept ubiquitin from E2 (specifically UBE2L3) onto their catalytic cysteine

• This forms a thioester intermediate before transferring ubiquitin to the substrate

• This mechanism resembles both RING and HECT-type E3 ligases

This hybrid mechanism provides additional regulatory control and specificity in substrate ubiquitination. The requirement for UBE2L3 as an E2 partner is also distinctive of RNF19B function .

What are the optimal methods for studying RNF19B-mediated ubiquitination?

When investigating RNF19B-mediated ubiquitination, researchers should consider:

• Ubiquitination assays:

  • In vivo ubiquitination can be assessed by co-immunoprecipitation followed by western blotting with anti-ubiquitin antibodies

  • Use of ubiquitin-specific antibodies (K48-linkage specific) for determining ubiquitin chain types

  • Proteasome inhibitors (MG132) can be included to prevent degradation of ubiquitinated proteins

• Expression systems:

  • Both overexpression and knockdown/knockout approaches should be employed

  • CRISPR-Cas9 knockout of RNF19B followed by re-expression of wild-type or mutant forms is effective

  • Key controls include catalytically inactive RNF19B (C316A mutation) and domain deletion constructs

• Protein stability assessment:

  • Cycloheximide chase assays (10 μg/mL) to inhibit new protein translation and examine target protein turnover

  • Compare protein stability in the presence and absence of RNF19B

What cellular models are most appropriate for studying RNF19B function?

Based on the available literature, the following cellular models have proven effective for studying different aspects of RNF19B biology:

For immune function studies, primary NK cells and macrophages from mice or humans represent physiologically relevant models, though they require stimulation with interferons or cytokines to induce optimal RNF19B expression . For biochemical studies of RNF19B-mediated ubiquitination, HEK293T cells with CRISPR-mediated knockout of both RNF19A and RNF19B provide a clean background for reconstitution experiments .

What are the challenges in developing recombinant RNF19B for in vitro studies?

Several challenges exist when working with recombinant RNF19B:

• Membrane association: RNF19B contains transmembrane domains that complicate protein purification and in vitro reconstitution

• Catalytic mechanism: As an RBR E3 ligase, RNF19B requires a properly folded RING1-IBR-RING2 domain with an accessible catalytic cysteine

• Complex formation: Some RNF19B functions may require additional cellular cofactors

• In vitro reconstitution: Despite multiple attempts, researchers have been unable to reconstitute ubiquitination of certain substrates (e.g., BRD1732) by RNF19B with recombinant proteins

To overcome these challenges, consider:

• Expression of truncated forms lacking transmembrane domains

• Co-expression with relevant binding partners

• Use of detergent-based extraction methods suitable for membrane proteins

• Inclusion of relevant E1 and E2 (UBE2L3) enzymes in reconstitution attempts

What are emerging areas of RNF19B research?

Several exciting research directions are emerging for RNF19B:

• Small molecule ubiquitination: The discovery that RNF19B can mediate ubiquitination of non-proteinaceous substrates (small molecules) opens new possibilities for directed ubiquitination strategies

• Cancer biomarker development: The correlation between RNF19B expression and cancer prognosis suggests potential as a diagnostic or prognostic biomarker

• Immune modulation: Further exploration of RNF19B's role in innate immunity could reveal new therapeutic targets for inflammatory diseases

• Substrate identification: Comprehensive proteomics approaches to identify the full range of RNF19B substrates beyond RAC1

How might RNF19B be targeted therapeutically?

Potential therapeutic approaches targeting RNF19B include:

• For cancer therapy (where RNF19B is downregulated):

  • Small molecule activators of RNF19B to enhance degradation of oncogenic substrates like RAC1

  • Gene therapy approaches to restore RNF19B expression

• For immune modulation:

  • Inhibitors of RNF19B to dampen excessive innate immune responses

  • Activators to enhance NK cell and macrophage function against pathogens or tumors

• Proteolysis-targeting chimeras (PROTACs):

  • Utilizing RNF19B's ability to ubiquitinate small molecules to develop novel targeted protein degradation technologies

  • Bifunctional compounds that recruit RNF19B to protein targets of interest